The aim of this study was to investigate the in vitro inhibitory effects of acanthoic acid (ACAN), isolated from Acanthopanax koreanum, on melanogenesis and its related enzymes such as tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 in B16 melanoma cells. We found that ACAN significantly attenuates melanin synthesis and reduces the activity of intracellular tyrosinase, the rate-limiting melanogenic enzyme. Western blot analysis showed that ACAN also decreases tyrosinase, TRP-1, and TRP-2 protein expression. In addition, ACAN significantly decreased the expression of microphthalmiaassociated transcription factor (MITF), a key regulator of melanogenesis. These results indicate that ACAN effectively inhibits melanin biosynthesis through down-regulation of MITF and thus could be useful as a new skin-whitening agent.
Melanogenesis is the physiological process that results in the synthesis of melanin pigments, which are secreted by melanocytes in the basal layer of the epidermis and play a crucial protective role against UV irradiation and oxidative stresses in the skin [1, 2] . However, abnormally excessive accumulation of melanin causes a number of skin diseases, including acquired hyperpigmentation such as melasma, freckles, postinflammatory melanoderma, and solar lentigo [3] . Therefore, the control of melanogenesis is an important strategy in the treatment of abnormal skin pigmentation for cosmetic and medicinal purposes [4] [5] [6] .
Melanin synthesis is mediated by melanocyte-specific enzymes such as tyrosinase (TYR), TYR-related protein (TRP)-1, and TRP-2. On the sequential pathway to melanin formation, TYR, a ratelimiting enzyme, catalyzes tyrosine to 3,4-dihydroxyphenylalanine and further oxidizes it to dopaquinone [7] [8] [9] . Therefore, TYR inhibitors may be useful in the treatment of abnormal pigmentation disorders and as skin-whitening agents in the cosmetic industry. Although a large number of pharmacological and cosmetic agents are available which inhibit TYR or other enzymes involved in melanogenesis, only a few are used for skin whitening because of their toxicity and unsatisfactory activity. Natural molecules derived from plant extracts overcome the side effects of anti-melanogenic agents. Therefore, the potential of natural products for cosmetic and medicinal purposes has been reevaluated and investigated [10] [11] .
During our search for effective melanin biosynthesis inhibitors from natural products [12] [13] [14] , we have found that acanthoic acid (ACAN), isolated from Acanthopanax koreanum, is a potent inhibitor of melanin biosynthesis. Acanthopanax species (Araliaceae) are widely distributed throughout Korea, Japan, China, and the far eastern region of Russia. Approximately 15 species of this genus grow wild on the Korean peninsula, including A. koreanum, a perennial plant native to Jeju Island. Its roots and stems have been used traditionally in Korea to increase strength, energy, and general well-being and in the treatment of rheumatism, diabetes, and hepatitis [15] [16] .
ACAN isolated from A. koreanum is a pimarane-type diterpene constituent and reportedly has a broad spectrum of biological activities such as antioxidant, anti-inflammatory, anti-carcinogenic, and hepatoprotective effects. We recently investigated the effects of ACAN on proliferation and apoptosis and their mechanisms in HL-60 human promyelocytic leukemia cells. However, the effects of ACAN on melanogenesis have not been examined thus far. Therefore, we evaluated the inhibitory activity of ACAN on melanin biosynthesis and melanogenic protein expression using B16F10 mouse melanocytes.
In this study, changes in melanin content in cells treated with ACAN were evaluated for anti-melanogenesis activity. We investigated its effects in B16 cells stimulated with α-MSH, which are the best characterized biologically relevant agents inducing melanogenesis. As shown in Fig. 1A , the melanin content of cells was significantly attenuated by ACAN in a dose-dependent manner. The commercial whitening agent, melasolv, was used as the positive control. It also inhibited melanogenesis in murine B16 melanoma cells.
Although a number of studies on melanogenic inhibitory compounds such as hydroquinone, kojic acid, and arbutin have been reported, these compounds sometimes irritate the skin and exhibit cell toxicity. Therefore, potent small molecular compounds that act as anti-melanogenic agents without compromising cytotoxicity must be found. To investigate the cytotoxicity of ACAN on cell proliferation, B16F10 mouse melanocytes were treated with various concentrations (25, 50, and 100 μM) of ACAN for 72 h. As shown in Figure 1B , no significant difference in cell proliferation was found between control and ACAN-treated cells, suggesting that the inhibitory effects of ACAN on melanin biosynthesis are not attributable to its cytotoxicity.
Cellular TYR is the major factor that stimulates melanin synthesis and ultimately induces melanogenesis. Therefore, we measured this activity to investigate the anti-melanogenic activity of ACAN in B16F10 cells. B16F10 cells were pretreated with ACAN at concentrations between 25 and 100 μM. ACAN treatment significantly reduced cellular TYR activity in a dose-dependent manner compared with that in controls ( Figure 2 ).
Human melanocytes are known to express TYR, TRP-1, and TRP-2. These proteins constitute a specific family of membrane proteins that are structurally related but have distinct enzyme functions. TRP-2 catalyzes the rearrangement of dopachrome to 5,6-dihydroxyindole-2-carboxylic acid, which TRP-1 oxidizes to a carboxylated indole-quinone. Both TRP enzymes work downstream from TYR in the melanin biosynthetic pathway [1] [2] [3] [4] [5] . To elucidate the anti-melanogenic mechanism of ACAN, we evaluated the expression of TYR, TRP-1, and TRP-2 using Western blot analysis. Compared with untreated controls, ACAN-treated cells showed dose-dependent decreases in TYR, TRP-1, and TRP-2 expression. These results clearly suggest that ACAN contributes to the inhibition of melanin biosynthesis by regulating the expression of TRP-1 and TRP-2, as well as TYR (Figure 3 ). Microphthalmia-associated transcription factor (MITF), a key regulator of melanocyte development, effectively transactivates the TYR, TRP-1, and TRP-2 genes. Therefore, the effect of ACAN on MITF expression was also evaluated in this study. As shown in Figure 3 , Western blot analysis showed that the upstream transcription factor MITF was down-regulated in a dose-dependent manner. MITF is a known specific transcription factor of the TYR gene family. The down-regulation of MITF is thought to affect the expression of all TYR-like genes, including TYR, TRP-1, and TRP-2. The present results suggest that MITF protein levels are reduced by ACAN. The anti-melanogenic effect of ACAN may be the result of down-regulation of MITF gene expression, which would then repress both the protein and gene expressions of TYR, TRP-1, and TRP-2. These results indicate that ACAN effectively inhibits melanin biosynthesis through down-regulation of MITF, and thus could be useful as a new skin-whitening agent.
Although the anti-melanogenic effect of ACAN was identified in this study, its detailed mechanism of action was not determined. In particular, the potential inhibitory mechanisms toward adenylyl cyclase activity and its signaling pathway need to be further evaluated in future studies. The major signaling pathway leading to melanin synthesis have been reported to be involved in the stimulation of adenylyl cyclase, followed by an increase in the cAMP level and activation of cAMP-dependent protein kinases A (PKAs). cAMP increases the expression of MITF melanocytespecific transcription factor crucial for melanocyte development and differentiation [17] [18] [19] . Therefore, it is possible that ACAN may inhibit the increment of cAMP level and activation of PKAs induced by α-MSH. However, we cannot exclude the possible involvement of the inhibition of other transcription factors.
In summary, we investigated the hypopigmentary effects of ACAN and related melanogenic activity. We found that ACAN inhibits melanogenesis in B16F10 mouse melanocyte by down-regulating TYR, TRP-1, and TRP-2 expression. Therefore, we suggest that ACAN may be a useful inhibitor of melanogenesis and have beneficial effects in the treatment of hyperpigmentation disorders such as melasma, freckles, postinflammatory melanoderma, and solar lentigo. However, the inhibitory mechanism of melanin production in B16F10 cells by ACAN remains unclear. Investigations of the exact mechanisms and further in vivo experiments are needed to evaluate the use of ACAN as a natural skin-whitening agent. 1, and 0:1). Purification of ACAN was undertaken as described previously [15] .
Experimental

Isolation of ACAN:
Cell culture: B16F10 mouse melanocytes were purchased from the Korean Cell Line Bank (Seoul, Korea). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (GIBCO, Inc., NY, USA) and 1% penicillinstreptomycin at 37°C in a humidified 95% air/5% CO 2 atmosphere.
Cell viability assay:
Cell viability was determined using the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells were seeded on 96-well plates, and drug treatment began 18 h after seeding. B16F10 murine melanoma cells were incubated with various concentration of ACAN for 72 h at 37°C in a humidified 95% air/5% CO 2 atmosphere. 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (1 mg/mL in phosphate-buffered saline[PBS]) was added to each well in a 1/10 volume of medium. Cells were incubated at 37°C for 4 h. Finally, the supernatant was removed, and the formazan crystals were dissolved in dimethyl sulfoxide. Absorbance was measured at 570 nm. The percentage of cells showing cytotoxicity was determined relative to that of the control group.
Melanin content assay: Cells of the murine melanoma cell line B16F10 plated at 1.0 × 10 5 cells/mL were stimulated with α-MSH (50 nM) and incubated with aliquots of ACAN (25, 50, and 100 µM) at 37°C for 72 h. The cells were then washed in ice-cold PBS. The samples were incubated at 80°C for 1 h in 1 mL of 1 N NaOH/10% dimethyl sulfoxide and then vortexed to solubilize the melanin; absorbance at 405 nm was then measured. Melanin content was determined based on the absorbance per µg of protein in the extract from each cell. The protein concentration of the cells was determined using a protein assay kit (Pierce, Rockford, IL, USA).
Western blot measurement of TYR, TRP-1, TRP-2, and MITF in melanoma B16/F10 cells:
Measurement of TYR, TRP-1, TRP-2, and MITF in melanoma B16/F10 cells using Western blot was undertaken as described previously [13] [14] . TYR and TRP expression were also determined with this method. B16 melanoma cells that had been stimulated with α-MSH (100 nM) were treated with ACAN (25, 50, and 100 µM) for 3 days. After treatment, the cells were collected and lysed with cell lysis buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 6% mercaptoethanol, 1% glycerol). Wholecell lysates (5 ×10 4 cell equivalents per lane) were separated with 7.5% SDS-polyacrylamide gel electrophoresis, as described previously, and transferred to a polyvinylidene fluoride membrane. The membrane was blocked with 5% skimmed milk in PBS containing 0.05% Tween 20. TYR, TRP-1, TRP-2, and MITF bands were detected with the rabbit polyclonal anti-TYR antibody (dilution 1:1000), rabbit polyclonal anti-TRP-1 antibody (dilution 1:1000), rabbit polyclonal anti-TRP-2 antibody, and rabbit polyclonal anti-MITF antibody (dilution 1:500), respectively, which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and then further incubated with horseradish peroxidaseconjugated anti-rabbit immunoglobulin G antibody at a 1:5,000 dilution. Bound antibodies were detected using an enhanced chemiluminescence kit (Amersham) following the manufacturer's instructions. Loading control was assessed using anti-β-actin antibody. Positive bands were analyzed using a gel image analysis instrument.
Determination of cellular TYR activity:
Cellular TYR activity was measured using the method of Yen et al. [17] , with modification. Briefly, the culture method for determining cellular TYR assay was similar to that for determining melanin content. After treatment with various concentrations of ACAN for 72 h, the cells were collected after treatment with trypsin-EDTA and centrifuged at 15,000 rpm for 15 min to obtain cell pellets. The pellet solutions were frozen and thawed twice and then centrifuged at 15,000 rpm for 15 min. Eighty μL supernatant was placed in a 96-well plate and mixed in 20 μL 0.2% 3,4-dihydroxyphenylalanine. After incubation for 1 h, the optical densities were measured at 475 nm using a microplate spectrophotometer. The inhibitory activity of ACAN-treated cells was presented as a percentage of activity in untreated cells.
Statistical analysis:
All data were obtained in triplicate and are presented as means ± standard error. Significant differences between treatments were determined with the Student's t-test in a 1-way analysis of variance.
